Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Manolito Castillo

Psychiatry Merced, CA Medical Doctor

NPI 1962585356 CMS profile 134942

2111 O St, Merced, CA 95340

Open in the dashboard

General payments

$4,530

244 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Manolito Castillo of Merced, CA is reported in the CMS Open Payments database as having received $4,530 across 244 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 88th percentile of Psychiatry profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $649 25
2024 General $654 28
2023 General $368 17
2022 General $681 30
2021 General $893 44
2020 General $712 38
2019 General $574 62

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Manolito Castillo
  • Psychiatry median
  • Middle half of Psychiatry
  • National median

In program year 2025, general payments to Manolito Castillo were reported at $649. Among 14,155 Psychiatry profiles paid that year, the median was $180 and the middle half received between $58 and $685.

Show as a table
Year Manolito Castillo Psychiatry median Middle half National median
2019 $574 $184 $59–$605 $163
2020 $712 $119 $36–$372 $114
2021 $893 $143 $43–$576 $132
2022 $681 $153 $50–$590 $149
2023 $368 $170 $56–$651 $160
2024 $654 $179 $57–$673 $164
2025 $649 $180 $58–$685 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Janssen Pharmaceuticals, Inc $1,408 63 payments
  2. Alkermes, Inc. $1,319 54 payments
  3. Otsuka America Pharmaceutical, Inc. $718 39 payments
  4. AbbVie, Inc. $284 13 payments
  5. Allergan Inc. $180 26 payments
  6. Takeda Pharmaceuticals U.S.A., Inc. $160 25 payments
  7. Sunovion Pharmaceuticals Inc. $149 8 payments
  8. ITI, Inc. $112 7 payments
  9. Vanda Pharmaceuticals Inc. $78 3 payments
  10. Lundbeck LLC $46 2 payments
  11. Other $76 4 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $4,530 244 payments
Products named General payments · program years 2019–2025
  1. INVEGA SUSTENNA $1,354 60 payments
  2. ARISTADA Cns $1,319 54 payments
  3. ARISTADA Cns $1,319 54 payments
  4. ARISTADA Cns $1,259 51 payments
  5. ARISTADA Cns $1,259 51 payments
  6. ARISTADA INITIO $1,015 42 payments
  7. ABILIFY MAINTENA $423 23 payments
  8. REXULTI $394 21 payments
  9. LYBALVI $363 15 payments
  10. VRAYLAR $259 12 payments
  11. Other $1,365 99 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 35 drugs

Part D claims

1,723

Median for Psychiatry: 574

Drug cost

$68,351

Median for Psychiatry: $27,624

Branded share of claims

17.1%

Median for Psychiatry: 17%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Trintellix Vortioxetine Hydrobromide Brand 52 $28,015
Lurasidone Hcl Generic 27 $9,017
Quetiapine Fumarate Generic 147 $2,797
Clonazepam Generic 196 $2,650
Aripiprazole Generic 37 $2,548
Doxepin Hcl Generic 57 $1,751
Desvenlafaxine Succinate Er Desvenlafaxine Succinate Brand 30 $1,713
Gabapentin Generic 54 $1,656
Bupropion Xl Bupropion Hcl Brand 62 $1,653
Fluoxetine Hcl Generic 67 $1,154

The 10 drugs with the highest cost, of 35 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 20,488 Part D prescribers listed as Psychiatry; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 7 billing codes

Paid by Medicare

$22,264

Medicare's payments for the services billed

Medicare patients

63

Average age 58

Services billed

319

37 women, 26 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Depression 68%
High blood pressure 62%
Arthritis 43%
Ischemic heart disease 25%
Diabetes 24%
Osteoporosis 19%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 8 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
INVEGA SUSTENNA
  • Janssen Pharmaceuticals, Inc $265
$265 — —
ARISTADA
  • Alkermes, Inc. $159
$159 — —
VRAYLAR
  • AbbVie, Inc. $80
$80 — —
ABILIFY ASIMTUFII
  • Otsuka America Pharmaceutical, Inc. $48
$48 — —
ABILIFY MAINTENA
  • Otsuka America Pharmaceutical, Inc. $48
$48 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 8 in the dashboard with a free account

Records

244 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Psychiatry in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record